{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:24:37Z","timestamp":1791095077766,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.vaccine.2005.07.014","type":"journal-article","created":{"date-parts":[[2005,7,22]],"date-time":"2005-07-22T16:00:15Z","timestamp":1122048015000},"page":"3735-3745","source":"Crossref","is-referenced-by-count":62,"title":["Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial"],"prefix":"10.1016","volume":"24","author":[{"given":"R.","family":"McKenzie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.I.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.S.","family":"Nabors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.L. Van De","family":"Verg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2005.07.014_bib1","first-page":"651","article-title":"Global burden of Shigella infections: implications for vaccine development and implementation of control strategies","volume":"77","author":"Kotloff","year":"1999","journal-title":"Bull WHO"},{"issue":"2","key":"10.1016\/j.vaccine.2005.07.014_bib2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/IAI.67.2.782-788.1999","article-title":"Strategy for cross-protection among Shigella flexneri serotypes","volume":"67","author":"Noriega","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2005.07.014_bib3","first-page":"457","article-title":"Studies on vaccination against bacillary dysentery","volume":"45","author":"Mel","year":"1971","journal-title":"Bull WHO"},{"issue":"7","key":"10.1016\/j.vaccine.2005.07.014_bib4","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/IAI.67.7.3437-3443.1999","article-title":"Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602","volume":"67","author":"Coster","year":"1999","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2005.07.014_bib5","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1128\/IAI.70.4.2016-2021.2002","article-title":"Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults","volume":"70","author":"Kotloff","year":"2002","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2005.07.014_bib6","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/IAI.72.2.923-930.2004","article-title":"Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers","volume":"72","author":"Katz","year":"2004","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2005.07.014_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/oxfordjournals.aje.a112277","article-title":"Shigellosis in custodial institutions. V. Effect of intervention with streptomycin-dependent Shigella sonnei vaccine in an institution with endemic disease","volume":"104","author":"Levine","year":"1976","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2005.07.014_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0264-410X(90)90094-3","article-title":"Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease","volume":"8","author":"Herrington","year":"1990","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2005.07.014_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/infdis\/125.1.5","article-title":"Immunity in shigellosis. I. Response of man to attenuated strains of Shigella","volume":"125","author":"DuPont","year":"1972","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2005.07.014_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(96)06255-1","article-title":"Double-blind vaccine-controlled radomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults","volume":"349","author":"Cohen","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2005.07.014_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1574-6968.1988.tb02363.x","article-title":"Non-replicating oral whole cell vaccine protective against enterotoxigenic Escherichia coli (ETEC) diarrhea: stimulation of anti-CFA (CFA\/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes","volume":"1","author":"Evans","year":"1988","journal-title":"FEMS Microbiol Immunol"},{"issue":"8684","key":"10.1016\/j.vaccine.2005.07.014_bib12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0140-6736(90)90080-O","article-title":"Field trial of oral cholera vaccines in Bangladesh: results from 3-year follow-up","volume":"335","author":"Clemens","year":"1990","journal-title":"Lancet"},{"issue":"8932","key":"10.1016\/j.vaccine.2005.07.014_bib13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(94)90755-2","article-title":"Protective efficacy of oral whole-cell\/recombinant-B-subunit cholera vaccine in Peruvian military recruits","volume":"344","author":"Sanchez","year":"1994","journal-title":"Lancet"},{"issue":"9047","key":"10.1016\/j.vaccine.2005.07.014_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0140-6736(96)06107-7","article-title":"Field trial of a locally produced, killed, oral cholera vaccine in Vietnam","volume":"349","author":"Trach","year":"1997","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2005.07.014_bib15","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/infdis\/158.2.372","article-title":"Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial","volume":"158","author":"Clemens","year":"1988","journal-title":"J Infect Dis"},{"issue":"8778","key":"10.1016\/j.vaccine.2005.07.014_bib16","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/0140-6736(91)92590-X","article-title":"Prevention of travellers\u2019 diarrhoea by oral B-subunit\/whole-cell cholera vaccine","volume":"338","author":"Peltola","year":"1991","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2005.07.014_bib17","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/infdis\/157.5.1068","article-title":"Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population","volume":"157","author":"Cohen","year":"1988","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2005.07.014_bib18","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1128\/JCM.29.2.386-389.1991","article-title":"Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis","volume":"29","author":"Cohen","year":"1991","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2005.07.014_bib19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/infdis\/165.4.785","article-title":"Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide","volume":"165","author":"Cohen","year":"1992","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2005.07.014_bib20","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1128\/IAI.59.7.2341-2350.1991","article-title":"Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides","volume":"59","author":"Oberhelman","year":"1991","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2005.07.014_bib21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/infdis\/166.1.158","article-title":"Age-specific prevalence of serum antibodies to the invasion plasmid and lipopolysaccharide antigens of Shigella species in Chilean and North American populations","volume":"166","author":"Van de Verg","year":"1992","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2005.07.014_bib22","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1128\/IAI.63.9.3642-3648.1995","article-title":"Increased protein secretion and adherence to HeLa cells by Shigella spp. following growth in the presence of bile salts","volume":"63","author":"Pope","year":"1995","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2005.07.014_bib23","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1128\/jb.169.6.2561-2569.1987","article-title":"Molecular cloning of invasion plasmid antigen (ipa) genes from Shigella flexneri: analysis of ipa gene products and genetic mapping","volume":"169","author":"Buysse","year":"1987","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2005.07.014_bib24","first-page":"83","article-title":"Bacterial lipopolysaccharides. Extractions with phenol-water and further applications of the procedure","volume":"5","author":"Westphal","year":"1965","journal-title":"Methods Carbohydr Chem"},{"issue":"5","key":"10.1016\/j.vaccine.2005.07.014_bib25","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1128\/IAI.63.5.1617-1623.1995","article-title":"Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity","volume":"63","author":"Dickinson","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2005.07.014_bib26","first-page":"367","article-title":"Experimental keratoconjunctivitis shigellosa","volume":"4","author":"Sereny","year":"1957","journal-title":"Acta Microbiol Acad Sci Hung"},{"issue":"1","key":"10.1016\/j.vaccine.2005.07.014_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4269\/ajtmh.1995.53.47","article-title":"Characteristics of Shigella sonnei infection of volunteers: signs, symptoms, immune responses, changes in selected cytokines and acute-phase substances","volume":"53","author":"Munoz","year":"1995","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.vaccine.2005.07.014_bib28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1651-2227.1999.tb01075.x","article-title":"Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis","volume":"88","author":"Chakrabarti","year":"1999","journal-title":"Acta Paediatr"},{"issue":"11","key":"10.1016\/j.vaccine.2005.07.014_bib29","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1128\/IAI.67.11.5841-5847.1999","article-title":"Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines","volume":"67","author":"Hartman","year":"1999","journal-title":"Infect Immun"},{"issue":"2122","key":"10.1016\/j.vaccine.2005.07.014_bib30","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/S0264-410X(03)00111-7","article-title":"Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition","volume":"21","author":"Mukhopadhaya","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2005.07.014_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/JB.90.1.63-68.1965","article-title":"Protection of Monkeys Against Experimental Shigellosis with Attenuated Vaccines","volume":"90","author":"Formal","year":"1965","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2005.07.014_bib32","series-title":"Validation of a volunteer model of shigellosis due to shigella sonnei. [Abstract]","author":"Kirkpatrick","year":"2000"},{"issue":"8","key":"10.1016\/j.vaccine.2005.07.014_bib33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.inf.0000078156.03697.a5","article-title":"Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in 1\u20134-year-old children","volume":"22","author":"Passwell","year":"2003","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X05006651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X05006651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T09:19:59Z","timestamp":1586337599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X05006651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":33,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0264410X05006651"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2005.07.014","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}